

## A Comprehensive Review

# The interplay of essential and toxic trace elements in prostate cancer: a comprehensive review of risk factors, prevention, and clinical implications

Kamran Zaidi<sup>1</sup>, Muhammad Rashid Jamal<sup>2</sup>, Qamar Zaman<sup>3</sup>, Sabahat Javaid<sup>4</sup>, Muhammad Bakir Hussain<sup>5</sup>

1. Associate Professor Urology Department, Lahore General Hospital, Lahore, Pakistan.
2. Senior Registrar Urology Department, Allama Iqbal Teaching Hospital Dera Ghazi Khan, Pakistan.
3. Senior Registrar Urology Department, Lahore General Hospital, Lahore, Pakistan.
4. Professor, Pathology Department, CMH Medical & Dental College Lahore, Pakistan.
5. PhD Scholar, Pathological Physiology Department, I.M Sechenov First Moscow State Medical University, Moscow Russia.

## ABSTRACT

Prostate cancer (PCa) is one of the most common cancers in men, and is influenced by genetic, hormonal, environmental, and lifestyle factors. Recent research has expanded the understanding of PCa initiation and progression, and has emphasized the importance of both essential and toxic trace elements in this process. Trace elements are naturally-occurring, and many essential trace elements, like zinc and selenium, may provide a protective effect through antioxidant and host defense mechanisms. However, excessive exposure to trace element toxicants may contribute to PCa carcinogenesis through increased oxyradicals, oxidative stress and direct DNA damage, as well as hormonal dysregulation. Several socio-demographic variables like age, race, and socioeconomic status have an effect on PCa risk and clinical outcomes, while lifestyle factors such as obesity, diet, smoking and alcohol consumption shape the progression of disease. Importantly, nutrient and trace elements may also function as diagnostic biomarkers for PCa, but inconsistencies in findings limit their clinical application. Prevention-focused approaches are possible through healthy living, avoidance of toxins, and balanced nutrition. The aim of this review is to explore roles of essential and toxic trace elements in prostate cancer risk, associated factors, diagnosis, and prevention. Future research should address population-specific differences, mechanistic pathways, and prospective studies to clarify trace element interactions in PCa risk, diagnosis, and therapy.

**Keywords:** Prostate Cancer, Trace Elements, Zinc, Copper, Risk factors, Preventions.

**How To Cite This Article:** Zaidi K, Jamal MR, Zaman Q, Javaid S, Hussain MB. The interplay of essential and toxic trace elements in prostate cancer: a comprehensive review of risk factors, prevention, and clinical implications. *Pak J Urol.* 2025;3(1):11–30.

## Corresponding Author: Kamran Zaidi

Senior Registrar Urology Department, Allama Iqbal Teaching Hospital Dera Ghazi Khan, Pakistan

**Email:** KamranZaididrkamranzaidi@yahoo.com

**ORCID:** <https://orcid.org/0009-0006-9168-5210>

## ARTICLE TRACKING

Received:	14- JULY -2025
Revision:	16-AUG-2025
Accepted:	21-SEP-2025
Published:	10-JAN- 2025
DOI:	<a href="https://doi.org/10.69885/pju.v4i1.109">10.69885/pju.v4i1.109</a>

## INTRODUCTION

Globally, PCa is the second most prevalent type of cancer and the fifth leading cause of cancer-related death among men [1,2]. The pathogenesis of PCa is multifactorial, and a complex interplay among genetic predisposition, hormonal changes, lifestyle choices, and environmental exposure has been recognized [3,4]. Over the last few years, there has been increased focus on trace elements in the development and progression of PCa [5]. Although PCa is considered one of the most common malignancies in men, Alterations associated with this include loss-of-function mutations in genes such as PTEN, TP53, and BRCA2. These alterations lead to uncontrolled cell growth and resistance to apoptosis [6,7]. Chronic inflammation caused by bacterial infections, lifestyle choices, or environmental toxins can cause continuous oxidative injury and gene mutations [8,9]. Trace elements can either augment or inhibit carcinogenesis depending on their concentrations and bioavailability. They mediate all these pathways, which ultimately contribute to prostate carcinogenesis. However, there remains an urgent need to unravel the genetic and molecular pathogenesis of PCa, which may help in the prevention and treatment of PCa [10]. This review examines the roles of these trace elements are hypothesized to play in the progression of PCa, their mechanism of action, their potential association with

PCa risk, and their possible diagnostic and preventive implications.

## Medical Factors effecting Prostate cancer

### Genetic Factors

Genetic susceptibility is an important risk factor for PCa. Germ-line mutations, with a presence in every cell of the body, account for about 10% of PCa cases and are referred to as hereditary PCa [11]. The Nordic Twin Study of Cancer [12,13] found that genetic factors estimate about 57% of PCa risk, establishing it as one of the most heritable cancers. Acquired mutations occur from either error during replication or environmental exposures, and they cause somatic tumor evolution through repetitive mutations in the tumor cell lineage [14].

### Hormonal Factor

Hormonal factors have important roles in the carcinogenesis of PCa. Elevated testosterone and its potent metabolite, dihydrotestosterone (DHT), are significant in PCa cell growth as higher androgen levels or androgen receptor (AR) sensitivity amplify tumor risk [15]. Androgen deprivation therapy (ADT) is a standard treatment; however, long-term utilization typically ends up with the development of castration-resistant prostate cancer (CRPC) [16].

### Medication

There has been considerable interest surrounding the

potential effects an anti-diabetic drug, metformin, could have on PCa as an antineoplastic agent [17]. While some studies have demonstrated an association between metformin and lowered PCa incidence and progression, while others have shown little to no association [18,19]. There is a significant proportion of metformin used globally which leaves a gap noted in the clinical literature and particularly cohort studies which have shown weak associations between metformin and PCa [20]. There is an enduring comprehensive clinical trial underway that aims to study the use of metformin as a standalone drug and in conjunction with androgen deprivation therapy for patients with metastatic disease [21]. Another pharmacological agent, statins, has also been associated with slowed progression of PCa. In a retrospective study of 11000 patients of a UK-based cohort, users of statins after diagnosis of cancer showed a 34% reduction in cancer-related mortality, particularly pronounced in users of statins before the diagnosis [22].

### **Metabolic Syndrome and Obesity**

Prostate cancer progression and mortality is critically augmented by both obesity and metabolic syndrome. According to a meta-analysis each incremental 5 kg/m<sup>2</sup> increase in BMI elevates the risk of dying from PCa by 20% [23,24]. The underlying causes of such phenomena may be connected to disrupt hormonal signaling [25,26]. Several studies have indicated that a

combination of hypertension, hyperglycemia, and central obesity are important in aggressive disease and recurrence [27]. In the Reduce trial, having 3 or more metabolic syndrome components showed strong associations to high-grade PCa [28].

### **Inflammation and Infectious Agents**

Chronic inflammation and infection contribute to pathophysiology of PCa. Similar inflammatory conditions such as prostatitis may induce changes in the connective tissue of the prostate, which enhances the risk of cancer [29,30]. Moreover, some of these infectious agents have been surveyed owing to their possible role in inflammation, resulting in tumor propagation in the prostate gland [31]. Understanding such relationships forms the basis of identifying at-risk populations and developing targeted interventions.

### **Alcohol, Narcotics, and Smoking**

The role of modifiable parameters, such as alcohol abuse and smoking, among other factors, has been widely researched. However, it should be noted that while a meta-analysis [32] involving 24 cohort studies has shown that there is no direct relationship between smoking and PCa incidence, heavy smokers have been shown to have an incidence of death from PCa that is 24%–30% higher than non-heavy smokers, where ex-smokers also appeared to have a higher risk. Alcohol intake has shown similar trends in risk with increasing

doses of PCa courtesy of a systematic review [33] of 340 studies suggesting a significantly increased risk with increasing doses.

### **Socio-demographic Factors**

Several socio-demographic factors can influence the diagnosis and treatment of PCa.

#### **Age**

Age is a significant risk factor for PCa and the likelihood of developing the disease increases with age. PCa is uncommon in men under 40 years of age; however, its incidence increases notably after that age [34,35]. This trend is consistent in both developed and developing countries. The risk of developing PCa increased from 0.5% in men aged 40-49 while 6.4 % in those aged 50 to 59, and further to 30.3 % in men aged 60 and 69 years old. Additionally, histological diagnosis rates are high in older age groups, with approximately 42.4 % of men aged 70–79 years showing signs of malignancy on examination [36]. For those aged  $\geq 80$  years, the ratio dropped by 3.8 %. Fortunately, most of these diagnoses are low-grade and low-volume, typically following slow progression without a significant risk of mortality [37]. Most cases being diagnosed in men aged  $\geq 65$  years. Older unmarried patients may be less likely to choose radical prostatectomy as a treatment option [38].

#### **Socioeconomic Status**

A lower socioeconomic status (SES), characterized by

low income and inadequate insurance coverage, is associated with a higher likelihood of being diagnosed with advanced-stage PCa. Research indicates that uninsured and Medicaid-insured patients are particularly vulnerable, often facing diagnoses at a younger age [39]. This discrepancy arises from several determinants of health-related social conditions, access to medical care, education, and other factors. Research has indicated that men from lower socioeconomic backgrounds are more likely to present with metastatic disease, with one analysis reporting that men at the 25th percentile of income had a 39% increased risk of advanced-stage diagnosis compared with men at the 75th percentile [40].

#### **Race and Ethnicity**

Incidences of PCa patch themselves by race, ethnicity, and place and it is Black men who suffer most because of the initial diagnosis, severity, and grim resultant death rates. In the USA, incidence among racial/ethnic populations varies three time and Black men are the highest diagnosed with a higher degree of likelihood resulting in a prostate carcinoma diagnosis [6,34]. Mortality for Black men with Carcinoma Prostate is 2.4 times greater than White men who are diagnosed statistically older, at a later stage of the disease, and with dire prediction [35,41]. This suggests that there is no avoiding the gaps inequities of race and ethnicity

country when primary care is offered.

### **Lifestyle related Factors**

Prostate cancer is affected by lifestyle factors. Diets that are high in meats, dairy, and sugary beverages are linked with a higher risk of PCa; whereas fish and foods high in tomatoes may be protective [42]. Maintaining a healthy weight and engaging in physical activity is important because obesity is associated with aggressive forms of the disease [43]. Incorporating lifestyle changes into primary prevention may reduce the incidence and thus, progression of PCa.

### **Ecological and Environmental Factors**

Prostate cancer is multifactorial in nature, and various ecological and environmental factors have been implicated in promoting this disease. However, these factors have played a significant role in the etiology of the disease [44,45]. Environmental exposures, including pesticides and pollutants, work hazards, lifestyle choices, and chronic inflammation, continuously aid in the causation and progression of pathology [46]. Knowledge of these effects is important for developing preventive strategies and improving patient outcomes.

### **Chemical exposure**

Environmental exposure to certain chemicals is related to an increased risk of PCa. Research has reported an association between pesticides, particularly

organochlorine pesticides such as DDT and heptachlor, and a greater incidence of PCa in men aged >50 [47]. A chlordecone, an insecticide, is considered a significant endocrine disruptor that may increase the risk of PCa [48]. These chemicals can interfere with hormonal pathways that promote the carcinogenesis of prostate cells.

### **Water Pollution**

Water quality is yet another environmental factor increasing the risk of PCa. Contaminants from fertilizers, such as per-fluorinated acids and nitrates, have shown a correlation with an increase in mortality from PCa [49]. These chemicals in drinking water have demonstrated to disrupt hormonal homeostatic and promote malignancy for the origin.

### **Occupational Hazards**

Certain occupations may expose employees to hazardous chemicals that could potentially increase PCa risk. Fire firefighters have been shown to be exposed to the byproducts of combustion, and then to a number of chemicals that are thought to increase risk of PCa [50]. Agricultural workers are also routinely exposed to pesticides and herbicides potentially for prolonged exposure, there is a body of literature demonstrating the association between pesticide and herbicide exposure and increased risk of PCa [51-52]. A cohort study [53] of male pesticide applicators demonstrates associations

between PCa and 45 pesticides used and corroborates workplace applications promotes their carcinogenic potential. Additionally, there may be genetic susceptibility which may alter their risk and add complexity to our understanding of the etiology of disease.

## **Diagnostic and Prognostic Value of Trace**

### **Elements in Prostate Cancer**

#### **Zinc (Zn)**

Zinc is an essential trace element that regulates growth, development, immunity, and the activity of over 3,000 proteins and > 2,000 signaling molecules [54-55]. Zinc is a modulator of DNA synthesis, DNA transcription, and apoptosis and is regulated by cellular transporters known as the Zrt- and Irt-like Proteins (ZIPs) and the zinc transporter (ZnT) to maintain cellular homeostasis [56-57]. The prostate has an optimal high level of zinc, which hints to its importance for prostate health [58-60]. As PCa reports about lower amounts of serum and tissue zinc levels in patients when compared to healthy controls suggest that zinc could play a role in a protective manner [5] [61-62]. In their function, zinc mediates apoptosis, regulates the cell cycle, inhibits the activity of the matrix metalloproteinases, acts as an antioxidant in health and disease [57] [63-64] however, in some populations, zinc levels are actually higher in PCa compared to healthy controls. These

inconsistencies could be influenced by differences in populations, assessment approaches, or disease stage [65]. Additional studies will further clarify the relationship of zinc in PCa prevention and/or therapy.

#### **Selenium**

Selenium is an essential trace element and has been reported to hold antioxidant and anticancer effects, which makes it interesting in PCa research [66]. Selenoprotein incorporate selenium, perform antioxidative properties, regulate the immune response, and protect against oxidative stress [67]. Selenium is involved in several key pathways related to PCa, such as androgen receptor signaling, apoptosis, and angiogenesis. This highlights selenium's possible role in prevention, controlling progression, or even therapy [68]. Previous studies have shown that men with PCa have lower levels of selenium in serum and tissue compared to healthy controls [5][59][69]. Higher levels of selenium were associated with lower rates of mortality [69]. Selenium works mechanistically by donating free radicals, antioxidation, and enhancing NK cell functions [70]. Although inconsistent associations have been reported between selenium and PCa, we need more research to determine the best selenium intake method for PCa prevention and understand its possible treatment effects.

#### **Copper (Cu)**

Copper is tracer element required for normal cellular activities while higher levels of copper may be associated with PCa. Higher copper has been reported in the serum and prostate tissue of both PCa patients when compared to controls [5,61] and higher copper concentrations were correlated with increased PCa mortality [69]. Copper increases angiogenesis and tumor growth by activating VEGF THAT promotes vascularization, supports extracellular matrix (ECM) formation, and activating copper-dependent enzymes like superoxide dismutase and ceruloplasmin that also increase oxidative stress resistance [71-74]. Therefore, defining and targeting copper homeostasis, utilizing chelation therapies such as tetrathiomolybdate are being studied as therapeutic approaches in PCa [75-76].

### **Cadmium (Cd)**

Cd is a carcinogen, with several mechanisms believed to cause PCa [77-78]. Men with PCa have higher levels of Cd in blood, urine, and prostate tissues than controls [79-81]. Cd is stored in tumor tissue and as explained will hinder androgen receptor (AR) signaling by binding to it. Because of this, AR loses its function and causes abnormal growth of prostate cells [77][80]. As an example, Cd generates reactive oxygen species when introduced to cells, which leads to oxidative stress. Due to this, DNA, proteins, and lipids get damaged and faulty [83]. Urinary Cd above recommended guidelines

increases PCa risk [80].

### **Arsenic (As)**

Arsenic, a toxic heavy metal, is a recognized carcinogen linked to PCa as well as skin, lung, and bladder cancers [11]. Elevated arsenic levels have been reported in PCa patients, both in serum and tumor tissues compared to adjacent healthy tissue [79][81]. Arsenic promotes carcinogenesis by suppressing DNA repair, inducing oxidative stress, generating reactive oxygen species that damage DNA, proteins, and lipids, and disrupting androgen receptor signaling critical for prostate cell growth and differentiation [11][5][61]. Public health interventions and environmental regulations aimed at reducing arsenic exposure could play a significant role in PCa prevention.

### **Lead (Pb)**

Lead is associated with a number of adverse health effects and disease conditions, including developmental delays, neurologic injury, and cancer [84]. While studies have examined the association between exposure to Pb and PCa, although there is still uncertainty about precisely how Pb might cause PCa, it is suggested that it disrupts the DNA repair processes, induces oxidative stress, and disrupts hormone signaling [84]. Pb has shown to inhibit the DNA repair enzymes causing DNA damage to accumulate leading to a greater likelihood of mutations. Pb can implement oxidative stress through

ROS generated by Pb which can damage DNA, proteins, and lipids [85]. Interventions in public health and environmental regulations that reduce Pb exposures, could represent an important opportunity for PCa prevention.

### **Iron (Fe)**

Iron is a required part of cellular metabolism, but excess Fe can mechanistically interface with carcinogenesis by promoting reactive oxygen species (ROS) through Fenton reactions [86]. It has been shown that in PCa tissues, there are higher levels of iron deposition, oxidative stress, and DNA damage than normal tissues [87]. Ferritin is iron storage protein is increased in PCa cells and promotes iron sequestration and tumor growth [88]. Aside from cancer risk, iron could be used therapeutically in the treatment of resistant PCa. Researchers are trying to develop means of inducing ferroptosis, a Fe-mediated form of regulated cell death, in order to specifically target resistant PCa cells [89]. In this case, the tumor cells die from excess iron that overloads the cells through ROS production. What is more, the iron storage gene FTH1 may be targeted for therapeutic development, meaning that manipulating iron metabolism may yield novel PCa therapeutic options [90].

### **Differential Diagnosis**

Trace element patterns in the serum, urine, and prostate

tissue have emerged as potential biomarkers for diagnosing and assessing the risk of PCa [91-92]. Lower serum zinc and selenium levels have been suggested to increase the risk of PCa [93-94]. PCa exhibited markedly lower serum zinc levels than healthy controls, thus making its deficiency a suspected risk factor [95]. Selenium is a very sensitive internalizing protein implicated in antioxidant health activity; hence, it carries the possibility of disrupting these trace element changes, showing biochemical changes that cause PCa progression [5]. Although trace elements hold promises as diagnostic tools, conventional methods remain the gold standard. These include Prostate-Specific Antigen (PSA) testing, CT scans, and MRIs. Despite its limitations in terms of specificity and sensitivity, PSA is widely used in clinical practice for PCa screening. CT and MRI provide vital information regarding the size of a tumor and its metastasis; hence, they are valuable in treatment planning [11]. However, their incorporation into routine screening might boost diagnostic accuracy, while providing more insights into individual risk profiles [96]. Further studies are needed to confirm trace elements as reliable PCa biomarkers. Combining conventional tests with novel biomarker strategies may improve PCa management.

### **Prevention and Treatment**

#### **Prevention**



Dietary and lifestyle modifications aimed at optimizing trace element status could be potential preventive strategies against PCa [42] [97-98]. Healthy lifestyle habits lead to prevent prostate cancer. Eating a balanced diet, exercising regularly, keeping a healthy weight, avoiding smoking and alcohol, and managing stress can reduce inflammation, oxidative damage, and hormone problems that may lead to cancer [99-100]. An adequate dose of minor elements, especially zinc and selenium, is very important, as deficiency in these minerals has been correlated with an increased risk of PCa. Zinc plays a significant role in the normal function of the prostate owing to its antioxidant properties, while mitigating the outcomes of oxidative stress associated with carcinogenesis [101]. Selenium, on the other hand, also has chemo preventive properties via mechanisms that boost immune responses and dampen inflammation, which are crucial for preventing cancer [5][66][68] [70][102].

Reducing exposure to toxic metals like cadmium, arsenic, and lead is important to lower PCa risk, as these metals cause oxidative stress and DNA damage [81][103]. Higher levels of these metals are linked to greater PCa incidence, highlighting environmental factors in prevention [104]. Zinc and selenium may have protective roles, but inconsistent study results call for further research to determine effective dosages and

supplementation forms for PCa prevention. Public health actions to limit toxin exposure may significantly impact incidence rates [105]. In addition, understanding the interaction between diet and environmental exposure is important in formulating an approach for the effective prevention of PCa.

## **Treatment**

Therapeutic modalities for PCa depend on the stage and risk factors for each patient. Options include choosing to active surveillance for patients with low risk, as well as radical prostatectomy, radiation therapy, and androgen deprivation therapy (ADT) for advanced disease [106-107]. Targeting trace element metabolism may help to stimulate a new approach to PCa treatment. Agents that chelate copper and compounds that are enriched with selenium show quite good promise in preclinical studies and are being investigated in clinical trials [94][108]. Further research is needed to target relevant trace-element-related pathways for therapeutic intervention.

## **Challenges and Future Directions**

### **Inconsistencies in the Literature**

The literature on trace elements and PCa is often inconsistent, with some studies reporting positive associations, others reporting negative associations, and others reporting no associations. These inconsistencies may be due to differences in study populations, methods of trace element assessment, and stage of PCa at the time

of diagnosis.

### Lack of Mechanistic Understanding

While progress has been made in understanding the mechanisms by which trace elements may influence PCa development, much remains unknown. Further research is needed to elucidate the specific molecular pathways involved and to identify key target genes and proteins.

### Need for Prospective Studies

Most of the studies reviewed were cross-sectional or case-control studies, which could not establish a core understanding. Prospective studies are needed to determine whether trace element status can predict PCa risk over time.

### Focus on Specific Populations

Future studies should examine specific at-risk populations for PCa, such as African-American men, White (European), and fair color (South Asian) population's diet and occupational differences as well as men with a family history of PCa. These populations likely have distinct trace element signatures and may respond differently to supplementation.

### Conclusion

Trace elements are likely complex and multifactorial in the pathogenesis of PCa even if our evidence base is still evolving. Based on the current understanding, it appears that imbalances in the status of trace elements could

play a role in PCa development and/or progression. It seems prudent to ensure adequate dietary intake of the essential trace elements (particularly zinc and selenium), and limit exposure to toxic heavy metals (i.e., cadmium, arsenic, and lead) as an important aspect of potential PCa prevention. However, prospective studies are needed to provide a clearer understanding of the role of trace elements in PCa, and develop those interventions for diagnosis, prevention, and treatment.

### Authors Contribution

**Zaidi K:** Conceptualization, Methodology, Software

**Jamal MR:** Data curation, Writing- Original draft preparation.

**Zaman Q & Javaid S:** Visualization, Investigation.

**Hussain MB:** Writing- Reviewing and Editing.

### References

1. Ahn HK, Lee YH, Koo KC. Current status and application of metformin for prostate cancer: a comprehensive review. *International journal of molecular sciences*. 2020 Nov 12;21(22):8540.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020 Jan;70(1):7-30.
3. Rawla P. Epidemiology of prostate cancer. *World journal of oncology*. 2019 Apr 20;10(2):63.
4. Costello LC, Franklin RB. A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in

- prostate cancer. *Archives of biochemistry and biophysics*. 2016 Dec 1; 611:100-12.
5. Saleh SA, Adly HM, Abdelkhaliq AA, Nassir AM. Serum levels of selenium, zinc, copper, manganese, and iron in prostate cancer patients. *Current urology*. 2020 Mar 20;14(1):44-9.
  6. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. *Cold Spring Harbor perspectives in medicine*. 2018 Dec 1;8(12): a030361.
  7. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H. Integrative clinical genomics of advanced prostate cancer. *Cell*. 2015 May 21;161(5):1215-28.
  8. Cheng H, Wang Y, Liu C, Wu T, Chen S, Chen M. Development and Verification of a Prostate Cancer Prognostic Signature Based on an Immunogenomic Landscape Analysis. *Frontiers in Oncology*. 2021 Sep 9; 11:711258.
  9. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. *Nature Reviews Cancer*. 2007 Apr;7(4):256-69.
  10. Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, Giovannucci E, Parmigiani G, Mucci LA. Family history of breast or prostate cancer and prostate cancer risk. *Clinical Cancer Research*. 2018 Dec 1;24(23):5910-7.
  11. Mustafa M, Salih AF, Illzam EM, Sharifa AM, Suleiman M, Hussain SS. Prostate cancer: pathophysiology, diagnosis, and prognosis. *IOSR J Dent Med Sci*. 2016;15(6):4-11.
  12. Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al., Familial risk and heritability of cancer among twins in Nordic countries. *Jama*. 2016 Jan 5;315(1):68-76.
  13. Eeles R, Goh C, Castro E, Bancroft E, Guy M, Olama AA, et al., The genetic epidemiology of prostate cancer and its clinical implications. *Nature reviews Urology*. 2014 Jan;11(1):18-31.
  14. Benafif S, Kote-Jarai Z, Eeles RA. A review of prostate cancer genome-wide association studies (GWAS). *Cancer Epidemiology, Biomarkers & Prevention*. 2018 Aug 1;27(8):845-57.
  15. Maranto C, Sabharwal L, Udhane V, Pitzen SP, McCluskey B, Qi S, et al., Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target AR signalling. *Science Advances*. 2024 Feb 28;10(9): eadi2742.

16. Mohler JL. A role for the androgen-receptor in clinically localized and advanced prostate cancer. *Best practice & research Clinical endocrinology & metabolism*. 2008 Apr 1;22(2):357-72.
17. Feng Z, Zhou X, Liu N, Wang J, Chen X, Xu X. Metformin use and prostate cancer risk: A meta-analysis of cohort studies. *Medicine*. 2019 Mar 1;98(12): e14955.
18. Tiruye T, O'Callaghan M, FitzGerald LM, Moretti K, Jay A, Higgs B, et al., Medication-based comorbidity measures and prostate cancer treatment selection. *Clinical Genitourinary Cancer*. 2024 Apr 1;22(2):599-609.
19. Fleshner NE, Bernardino RM, Lajkocz K, Saad F, Izawa J, Drachenberg D, et al., A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study. *Journal of Clinical Oncology*, 2024; 41(6), 307.
20. Bossio S, Urlandini L, Perri A, Conforti F, Aversa A, Di Agostino S, Rago V. Prostate cancer: emerging modifiable risk factors and therapeutic strategies in the management of advanced cancer. *Life*. 2024 Aug 30;14(9):1094.
21. Ruplin A, Segal E, McFarlane T. Review of drug-drug interactions in patients with prostate cancer. *Journal of Oncology Pharmacy Practice*. 2024 Oct;30(6):1057-72.
22. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, Azoulay L. Use of statins and the risk of death in patients with prostate cancer. *Journal of Clinical Oncology*. 2014 Jan 1;32(1):5-11.
23. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. *Cancer prevention research*. 2011 Apr 1;4(4):486-501.
24. Allott EH, Hursting SD. Obesity and cancer: mechanistic insights from transdisciplinary studies. *Endocrine-related cancer*. 2015 Sep 15;22(6): R365.
25. Smith LA, O'Flanagan CH, Bowers LW, Allott EH, Hursting SD. Translating mechanism-based strategies to break the obesity- cancer link: a narrative review. *Journal of the Academy of Nutrition and Dietetics*. 2018 Apr 1;118(4):652-67.
26. Liao Q, Long C, Deng Z, Bi X, Hu J. The role of circulating adiponectin in prostate cancer: a meta-analysis. *The international journal of biological markers*. 2015 Jan;30(1):22-31.

27. Gacci M, Russo GI, De Nunzio C, Sebastianelli A, Salvi M, Vignozzi L, et al., Meta-analysis of metabolic syndrome and prostate cancer. *Prostate cancer and prostatic diseases*. 2017 Jun;20(2):146-55.
28. Sourbeer KN, Howard LE, Andriole GL, Moreira DM, Castro-Santamaria R, Freedland SJ, Vidal AC. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. *BJU international*. 2015 May;115(5):736-43.
29. Archer M, Dogra N, Kyprianou N. Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. *Cancers*. 2020 Oct 15;12(10):2984.
30. Li W, Wang J. The current state of inflammation-related research in prostate cancer: a bibliometric analysis and systematic review. *Frontiers in Oncology*. 2024 Sep 17; 14:1432857.
31. Jiang J, Li J, Yunxia Z, Zhu H, Liu J, Pumill C. The role of prostatitis in prostate cancer: meta-analysis. *PloS one*. 2013 Dec 31;8(12):e85179.
32. Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. *American journal of public health*. 2010 Apr;100(4):693-701.
33. Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. *BMC cancer*. 2016 Nov 15;16(1):845.
34. Novosel M, Smani S, Marks VA, Jeong F, Sprenkle P, Leapman M. Associations between patient sociodemographic factors and non-treatment for localized prostate cancer. *Journal of Clinical Oncology*. 2023 ;41(6), 307.
35. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International journal of cancer*. 2015 Mar 1;136(5): E359-86.
36. Chin HW, Kim J, Rasp G, Hristov B. Prostate cancer in seniors: part 1: epidemiology, pathology, and screening. *Federal Practitioner*. 2015 May;32(Suppl 4):41S.
37. Ng KL. The etiology of prostate cancer. *Exon Publications*. 2021 May 27:17-27.
38. Pereira-Lourenço M, e Brito DV, Peralta JP, Godinho R, Conceição P, et al., Influence of sociodemographic factors on treatment's choice for localized prostate cancer in Portugal.

*Archivio Italiano di Urologia e Andrologia.*

2020 Apr 6;92(1):45-9.

39. Singh S, Sridhar P. A narrative review of sociodemographic risk and disparities in screening, diagnosis, treatment, and outcomes of the most common extrathoracic malignancies in the United States. *Journal of thoracic disease.* 2021 Jun;13(6):3827.
40. Coughlin SS. A review of social determinants of prostate cancer risk, stage, and survival. *Prostate international.* 2020 Jun 1;8(2):49-54.
41. Smani S, Novosel M, Sutherland R, Jeong F, Jalfon M, Marks V, Rajwa P, Nolzco JJ, Washington SL, Renzulli II JF, Sprenkle P. Association between sociodemographic factors and diagnosis of lethal prostate cancer in early life. In *Urologic Oncology: Seminars and Original Investigations* 2024 Feb 1 (Vol. 42, No. 2, pp. 28-e9). *Elsevier*.
42. Lin PH, Aronson W, Freedland SJ. An update of research evidence on nutrition and prostate cancer. In *Urologic Oncology: Seminars and Original Investigations* 2019 Jun 1 (Vol. 37, No. 6, pp. 387-401). *Elsevier*.
43. García-Perdomo HA, Gómez-Ospina JC, Chaves-Medina MJ, Sierra JM, Gómez AM, Rivas JG. Impact of lifestyle in prostate cancer patients. What should we do? *International braz j urol.* 2022 Mar 11;48(2):244-62.
44. Hussain MB, Ghaleb SH, Mahjabeen MR, Rashid S, Durrani S, Rasheed N, Munir A. Evaluating the impact of smog-induced pollution on trace element concentrations in blood. *Afr. j. biol. Sci.* 2024 Dec 9; 6 (16): 1511-1528 (doi: 0.48047/AFJBS.6.16.2024.1511-1528).
45. Wiese D, DuBois TD, Sorice KA, Fang CY, Ragin C, Daly M, Reese AC, Henry KA, Lynch SM. An exploratory analysis of the impact of area-level exposome on geographic disparities in aggressive prostate cancer. *Scientific Reports.* 2024 Jul 29;14(1):16900.
46. Li J, Deng Z, Soerensen SJ, Kachuri L, Cardenas A, Graff RE, Leppert JT, Langston ME, Chung BI. Ambient air pollution and urological cancer risk: A systematic review and meta-analysis of epidemiological evidence. *Nature Communications.* 2024 Jun 15;15(1):5116.
47. Ferrís-I-Tortajada J, Berbel-Tornero O, García-i-Castell J, López-Andreu JA, Sobrino-Najul E, Ortega-García JA. Non-dietary environmental risk factors in prostate cancer. *Actas Urológicas Españolas (English Edition).* 2011 May 1;35(5):289-95.

48. Brureau L, Multigner L, Hamdy F, Blanchet P, Bryant R. Organochlorine pesticide exposure and risk of prostate cancer development and progression: a systematic review. *F1000Research*. 2021 Apr 1; 10:262.
49. Donat-Vargas C, Kogevinas M, Castaño-Vinyals G, Pérez-Gómez B, Llorca J, Vanaclocha-Espí M, Fernandez-Tardon G, Costas L, Aragonés N, Gómez-Acebo I, Moreno V. Long-term exposure to nitrate and trihalomethanes in drinking water and prostate cancer: a multicase–control study in Spain (MCC-Spain). *Environmental Health Perspectives*. 2023 Mar 8;131(3):037004.
50. Lee DJ, Ahn S, McClure LA, Caban-Martinez AJ, Kobetz EN, Ukani H, Boga DJ, Hernandez D, Pinheiro PS. Cancer risk and mortality among firefighters: a meta-analytic review. *Frontiers in Oncology*. 2023 May 12; 13:1130754.
51. Zhang R, Hu S, Ma C, Zhang T, Li H. Laser-induced breakdown spectroscopy (LIBS) in biomedical analysis. *TrAC Trends in Analytical Chemistry*. 2024 Dec 1; 181:117992.
52. Manrique J, Garrido P, Velasco J. Laser-induced breakdown spectroscopy in biological samples: a review of experiments with soft tissues. *Atoms*. 2024 Apr 1;12(4):21.
53. Alavanja MC, Samanic C, Dosemeci M, Lubin J, Tarone R, Lynch CF, Knott C, Thomas K, Hoppin JA, Barker J, Coble J. Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. *American journal of epidemiology*. 2003 May 1;157(9):800-14.
54. Sugimoto R, Lee L, Tanaka Y, Morita Y, Hijioka M, Hisano T, Furukawa M. Zinc deficiency as a general feature of cancer: a review of the literature. *Biological Trace Element Research*. 2024 May;202(5):1937-47.
55. Patil R, Sontakke T, Biradar A, Nalage D. Zinc: an essential trace element for human health and beyond. *Food Health*. 2023;5(3):13.
56. Skalnaya MG, Skalny AV. Essential trace elements in human health: a physician's view. Tomsk: Publishing House of Tomsk State University. 2018; 224:1-222.
57. Oteiza PI. Zinc and the modulation of redox homeostasis. *Free Radical Biology and Medicine*. 2012 Nov 1;53(9):1748-59.
58. Zaichick V, Zaichick S. Prostatic tissue levels of 43 trace elements in patients with prostate adenocarcinoma. *Cancer and Clinical Oncology*. 2016;5(1):79-94.

59. Singh CK, Malas KM, Tydrick C, Siddiqui IA, Iczkowski KA, Ahmad N. Analysis of zinc-exporters expression in prostate cancer. *Scientific reports*. 2016 Nov 11;6(1):36772.
60. Singh V, Madeshiya AK, Ansari NG, Singh MK, Abhishek A. CYP1A1 gene polymorphism and heavy metal analyses in benign prostatic hyperplasia and prostate cancer: An explorative case-control study. In *Urologic Oncology: Seminars and Original Investigations* 2023 Aug 1 (Vol. 41, No. 8, pp. 355-e9). *Elsevier*.
61. khedir Abdelmajid LM, Hessen RI, Dafalla AM, Hassan MI, Mohammed YA. Serum Zinc and Copper Levels among Patients with Prostatic Cancer Attending National Cancer Institute, Gezira University, Sudan. *Sudan Medical Laboratory Journal*. 2022 Dec 23;10(2):69-77.
62. Amadi C, Aleme BM. The prevalence of zinc deficiency among men with and without prostate cancer in Port Harcourt, Nigeria. *Nutrition and cancer*. 2020 Aug 17;72(6):1018-25.
63. Costello LC, Franklin RB, Feng P, Tan M, Bagasra O. Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States). *Cancer Causes & Control*. 2005 Oct;16(8):901-15.
64. Prasad AS. Zinc is an antioxidant and anti-inflammatory agent: its role in human health. *Frontiers in nutrition*. 2014 Sep 1; 1:14.
65. Igbokwe M, Salako A, Badmus T, Obiajunwa E, Olasehinde O, Igbokwe C, David R. Tissue Zinc Concentration in Prostate Cancer: Relationship with Prostate Specific Antigen and Gleason Score in a Cohort of Nigerian Men. *Asian Pacific Journal of Cancer Biology*. 2021 Jun 6;6(2):147-53.
66. Rayman MP. Selenium and human health. *The Lancet*. 2012 Mar 31;379(9822):1256-68.
67. Mariotti M, Gladyshev VN. Selenocysteine-containing proteins. In *Redox Chemistry and Biology of Thiols* 2022 Jan 1 (pp. 405-421). Academic Press.
68. Jiang J, Chen B, Tang B, Wei Q. Selenium in prostate cancer: prevention, progression, and treatment. *Pharmaceuticals*. 2023 Sep 5;16(9):1250.
69. Pietrzak S, Marciniak W, Derkacz R, Matuszczak M, Kiljańczyk A, Baszuk P, Bryśkiewicz M, Sikorski A, Gronwald J, Słojewski M, Cybulski C. Correlation between selenium and zinc levels and survival among prostate cancer patients. *Nutrients*. 2024 Feb 14;16(4):527.



70. Liu T, Xu L, He L, Zhao J, Zhang Z, Chen Q, Chen T. Selenium nanoparticles regulates selenoprotein to boost cytokine-induced killer cells-based cancer immunotherapy. *Nano Today*. 2020 Dec 1; 35:100975.
71. Cong Y, Li N, Zhang Z, Shang Y, Zhao H. Cuproptosis: molecular mechanisms, cancer prognosis, and therapeutic applications. *Journal of Translational Medicine*. 2025 Jan 22;23(1):104.
72. Bian C, Zheng Z, Su J, Chang S, Yu H, Bao J, Xin Y, Jiang X. Copper homeostasis and cuproptosis in tumor pathogenesis and therapeutic strategies. *Frontiers in Pharmacology*. 2023 Sep 12; 14:1271613.
73. Tisato V, Gallo S, Melloni E, Celeghini C, Passaro A, Zauli G, Secchiero P, Bergamini C, Trentini A, Bonaccorsi G, Valacchi G. TRAIL and ceruloplasmin inverse correlation as a representative crosstalk between inflammation and oxidative stress. *Mediators of inflammation*. 2018;2018(1):9629537.
74. Kong R, Sun G. Targeting copper metabolism: a promising strategy for cancer treatment. *Frontiers in Pharmacology*. 2023 Jul 26;14:1203447.
75. Ishida S, Andreux P, Poitry-Yamate C, Auwerx J, Hanahan D. Bioavailable copper modulates oxidative phosphorylation and growth of tumors. *Proceedings of the National Academy of Sciences*. 2013 Nov 26;110(48):19507-12.
76. Brewer GJ. The use of copper-lowering therapy with tetrathiomolybdate in medicine. *Expert opinion on investigational drugs*. 2009 Jan 1;18(1):89-97.
77. Neslund-Dudas CM, McBride RB, Kandegedara A, Rybicki BA, Kryvenko ON, Chitale D, Gupta N, Williamson SR, Rogers CG, Cordon-Cardo C, Rundle AG. Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. *Journal of Trace Elements in Medicine and Biology*. 2018 Jul 1; 48:233-8.
78. Waalkes MP. Cadmium carcinogenesis. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*. 2003 Dec 10;533(1-2):107-20.
79. Drozd-Afelt JM, Koim-Puchowska B, Kaminski P. Concentration of trace elements in blood of Polish patients with prostate cancer. *Environmental Toxicology and Pharmacology*. 2024 Apr 1; 107:104425.

80. Bede-Ojimadu O, Nnamah N, Onuegbu J, Grant-Weaver I, Barraza F, Orakwe J, Abiahu J, Orisakwe OE, Nriagu J. Cadmium exposure and the risk of prostate cancer among Nigerian men: Effect modification by zinc status. *Journal of Trace Elements in Medicine and Biology*. 2023 Jul 1; 78:127168.
81. Tyagi B, Chandrasekaran B, Tyagi A, Shukla V, Saran U, Tyagi N, Talluri S, Juneau AD, Fu H, Ankem MK, Damodaran C. Exposure of environmental trace elements in prostate cancer patients: A multiple metal analysis. *Toxicology and Applied Pharmacology*. 2023 Nov 15; 479:116728.
82. Rapisarda V, Miozzi E, Loreto C, Matera S, Fenga C, Avola R, Ledda C. Cadmium exposure and prostate cancer: insights, mechanisms and perspectives. *Front Biosci* (Landmark Ed). 2018 Mar 1;23(9):1687-700.
83. Pal D, Suman S, Kolluru V, Sears S, Das TP, Alatassi H, Ankem MK, Freedman JH, Damodaran C. Inhibition of autophagy prevents cadmium-induced prostate carcinogenesis. *British Journal of Cancer*. 2017 Jun;117(1):56-64.
84. ATSDR T. ATSDR (Agency for toxic substances and disease registry). Prepared by clement international corp., under contract. 2000; 205:88-0608.
85. Ebrahimi M, Khalili N, Razi S, Keshavarz-Fathi M, Khalili N, Rezaei N. Effects of lead and cadmium on the immune system and cancer progression. *Journal of Environmental Health Science and Engineering*. 2020 Jun;18(1):335-43.
86. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. *BMC medical genomics*. 2009 Jan 8;2(1):2.
87. Gao G, Li J, Zhang Y, Chang YZ. Cellular iron metabolism and regulation. *Brain iron metabolism and CNS diseases*. 2019 Aug 28:21-32.
88. Torti SV, Torti FM. Iron and cancer: more ore to be mined. *Nature Reviews Cancer*. 2013 May;13(5):342-55.
89. Ying J, Wang B, Han S, Song J, Liu K, Chen W, Sun X, Mao Y, Ye D. Genetically predicted iron status was associated with the risk of prostate cancer. *Frontiers in Oncology*. 2022 Dec 6; 12:959892.
90. Chan JJ, Kwok ZH, Chew XH, Zhang B, Liu C, Soong TW, Yang H, Tay Y. A FTH1 gene:

- pseudogene: microRNA network regulates tumorigenesis in prostate cancer. *Nucleic acids research*. 2018 Feb 28;46(4):1998-2011.
91. Zang Z, Liu X, Wang M, Wang Z. The Application of Inductively Coupled Plasma Mass Spectrometry in Cancer Research. *Critical Reviews in Analytical Chemistry*. 2025 Feb 4:1-25.
  92. Skalny AV, Korobeinikova TV, Aschner M, Baranova OV, Barbounis EG, Tsatsakis A, Tinkov AA. Medical application of laser-induced breakdown spectroscopy (LIBS) for assessment of trace element and mineral in biosamples: Laboratory and clinical validity of the method. *Journal of Trace Elements in Medicine and Biology*. 2023 Sep 1; 79:127241.
  93. Liu R, Zhang Q, Yan X, Lv Y. A critical review on the relevance, essentiality, and analytical techniques of trace elements in human cancer. *Metallomics*. 2025 Feb;17(2): mfafo05.
  94. Zaichick V, Zaichick S. Trace Elements of Expressed Prostatic Secretions as a Source for Biomarkers of Prostate Cancer. *Journal of Clinical Research in Oncology*. 2018;1(1):1-7.
  95. Tshoni UA, Mbonane TP, Rathebe PC. The role of trace metals in the development and progression of prostate cancer. *International journal of molecular sciences*. 2024 Oct 5;25(19):10725.
  96. Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA. Prostate Cancer, Version 3.2024. *Journal of the National Comprehensive Cancer Network: JNCCN*. 2024 Apr 1;22(3):140-50.
  97. Matsushita M, Fujita K, Nonomura N. Influence of diet and nutrition on prostate cancer. *International journal of molecular sciences*. 2020 Feb 20;21(4):1447.
  98. Ziglioli F, Patera A, Isgrò G, Campobasso D, Guarino G, Maestroni U. Impact of modifiable lifestyle risk factors for prostate cancer prevention: a review of the literature. *Frontiers in Oncology*. 2023 Sep 8; 13:1203791.
  99. Sharifi-Rad M, Anil Kumar NV, Zucca P, Varoni EM, Dini L, Panzarini E, Rajkovic J, Tsouh Fokou PV, Azzini E, Peluso I, Prakash Mishra A. Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of chronic diseases. *Frontiers in physiology*. 2020 Jul 2; 11:552535.
  100. Yang X, Chen H, Zhang S, Chen X, Sheng Y, Pang J. Association of cigarette smoking habits with the risk of prostate cancer: a systematic review

- and meta-analysis. *BMC Public Health*. 2023 Jun 15;23(1):1150.
101. Fu H, Murali A, Damodaran C. Exposure of environmental trace elements in prostate cancer patients: Risk analysis in multiple levels. In *Urologic Oncology: Seminars and Original Investigations* 2024 Mar 1 (Vol. 42, p. S88). *Elsevier*.
102. Christensen MJ. Selenium and prostate cancer prevention: what next—if anything? *Cancer prevention research*. 2014 Aug 1;7(8):781-5.
103. Njale E, Shilla DJ, Dharsee N, Mahugija JA, Mbare NS. Association between single and mixed exposure to potentially toxic trace metals and the risk of prostate cancer: a case–control study in Tanzania. *Environmental Geochemistry and Health*. 2025 Jun;47(6):1-8.
104. Kannan A, Venkatesvaran H, Ananthakrishnan D, Mayavan A, Gandhi S. An early detection of prostate cancer drug in water to prevent loss of biodiversity. *Process Safety and Environmental Protection*. 2021 Jul 1; 151:51-62.
105. Popescu E, Stanescu AM. Trace elements and cancer. *Mod. Med*. 2019;26(4):169-77.
106. Anderson EM, Gu L, Oyekunle T, De Hoedt AM, Wiggins E, Gay CJ, Lu DJ, Daskivich TJ, Freedland SJ, Zumsteg ZS, Csizmadia I. Lifestyle and sociodemographic factors associated with treatment

choice of clinically localized prostate cancer in an equal access healthcare system. *Prostate Cancer and Prostatic Diseases*. 2022 Sep;25(3):593-5.

107. Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. *JAMA oncology*. 2015 Jul 1;1(4):495-504.

108. Zaichick V, Zaichick S. Significance of trace element quantities in the prostatic secretion of patients with chronic prostatitis and prostate cancer. *JBRR*. 2019;2(1):56-61.



#### Licensing and Copyright Statement

All articles published in the Pakistan Journal of Urology are licensed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0) This license allows users to share (copy and redistribute) and adapt (remix, transform, and build upon) the published material for any purpose, including commercial, provided appropriate credit is given to the original author(s) and the source (Pakistan Journal of Urology), link to the license is provided, and any changes made are indicated. This work is licensed under a: [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/). © The Author(s) 2025.

**Publisher:** Institute of Kidney Diseases and Pakistan Association of Urological Surgeons (PAUS)